Clinical trial
Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043)
NCT00082524 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00082524 |
|---|---|
| Title | Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) |
| Official title | A Multicenter, Open-Label, Noncomparative Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in Children With Documented Candida or Aspergillus Infections |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aspergillosis, Candidiasis |
| Intervention type | Drug |
| Interventions | caspofungin acetate |
| Enrollment | 50 |
| Start date | Apr 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | May 13, 2004 |
| Last update posted | Feb 23, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: